Non-motor fluctuations in People with Parkinson’s considering Deep Brain Stimulation surgery
Objective: In this study we examine non-motor symptom (NMS) fluctuations reported by People with Parkinson’s (PWP) pursuing Deep Brain Stimulation (DBS) surgery using the MDS…Case reports of first experiences worldwide with novel continuous oral levodopa dental pump in Parkinson’s Disease Patients
Objective: To assess the safety, tolerability, and pharmacokinetics (PK) of a novel continuous levodopa-carbidopa oral pump (LCOP) delivery system in patients with early PD. Background:…Psychometric characteristics of the Neuropsychiatric Fluctuation Scale
Objective: To evaluate the psychometric properties of the Neuropsychiatric fluctuation scale (NFS) for Parkinson’s disease (PD). Background: Neuropsychiatric fluctuations (NpsyF) in PD are frequent and…Quality of life and patient reported outcomes with subcutaneous levodopa/carbidopa infusion: Findings from the ND0612 BeyoND study
Objective: To review quality of life and other patient reported outcomes data from the ND0612 BeyoND study. Background: ND0612 is in development as a continuous,…Long-term safety of continuous levodopa/carbidopa infusion with ND0612: Data from patients who continued past one year in the BeyoND study
Objective: To report long-term safety and tolerability data from the ongoing BeyoND study (NCT02726386) for patients who continued treatment past the one-year primary endpoint. Background:…Collective expert perspectives on the use of safinamide as adjunctive therapy for Parkinson’s disease in Japan: Online-based Delphi approach
Objective: To summarize opinions on the optimal patient profile and methods of using safinamide in common clinical scenarios, Japanese movement disorder specialists with expertise in…Basal forebrain contribution to cognitive deficits during medication “off” state in Parkinson’s disease
Objective: We sought to determine whether structural integrity of cholinergic Basal Forebrain (BF) was associated with subjective cognitive deficits experienced during medication “off” time Parkinson’s…Effect of KW-6356, a novel adenosine A2A receptor antagonist/inverse agonist, on motor and non-motor symptoms in Parkinson’s disease patients as an adjunct to levodopa therapy: Results of Phase 2b study
Objective: To evaluate the efficacy and safety of KW-6356 in Parkinson’s disease (PD) patients with levodopa therapy, irrespective of the presence of wearing-off (WO). Background:…Improving the patient self-awareness of the first motor fluctuations in early Parkinson’s disease with a wearable sensor
Objective: We aim to assess if the use of a wearable sensor can increase the patient and caregiver self-awareness of the first motor fluctuations (MF).…Safinamide as an adjunct to Levodopa Therapy in Asian and Caucasian Patients with Parkinson’s Disease and Motor Fluctuations: A post-hoc Analysis of the SETTLE study
Objective: This study evaluated the efficacy and safety outcomes of safinamide as a levodopa adjunct therapy in Asian and Caucasian patients with Parkinson’s disease. Background:…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 26
- Next Page »